GENOMIC HEALTH INC Form SC 13G/A February 14, 2012

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Amendment No. 1)\*

Under the Securities Exchange Act of 1934

Genomic Health, Inc.—
(Name of Issuer)

Common Stock, par value \$0.0001 Per Share (Titles of Class of Securities)

37244C101 (CUSIP Number)

December 31, 2011 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

o Rule 13d-1(c)

x Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

<sup>\*</sup> The remainder of this cover page shall be filled out of a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

13G

CUSIP No. 37244C101

Issuer's Form 10-Q, dated November 8, 2011.

		110.312	
1	NAME OF F	REPORTING	PERSON
	I.R.S. IDEN'	<b>TIFICATION</b>	NO. OF ABOVE PERSON (ENTITIES ONLY)
			S) Advisors, Inc.
2			IATE BOX IF A MEMBER OF A GROUP*
2		L AI I KOI KI	IATE DOA II' A WIEWIDER OF A GROUT
	(a) o		
	(b) o		
3	SEC USE O	NLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION		
	Delaware		
	Delaware	5	SOLE VOTING POWER
		3	SOLE VOTING FOWER
	NUMBER OF		-0-
	SHARES	6	SHARED VOTING POWER
	BENEFICIALLY		
	OWNED BY		1,410,273
	EACH	7	SOLE DISPOSITIVE POWER
	REPORTING	,	SOLL BISTOSTITY LTO WERK
	PERSON		-0-
	FERSON		-0-
	*****	0	GIA DED DIGDOGENIE DOMED
	WITH:	8	SHARED DISPOSITIVE POWER
			1,410,273
9	AGGREGA'	TE AMOUNT	Γ BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,410,273		
	1,110,270		
10	CHECK BO	V IETUE AC	GGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* o
11	PERCENT (	JF CLASS RI	EPRESENTED BY AMOUNT IN ROW 9
	4.8% (1)		
12	TYPE OF R	EPORTING F	PERSON*
	CO		
*SE	E INSTRUCTIONS B	SEFORE FILL	ING OUT
	L II (STITE CITOTED D	LI OILL I IEL	20.000
(1)	Događ on a total af 3	00 542 224 ab	organ of Common Stock outstanding as of October 21, 2011 as removed as the
(1)	Based on a total of 29,542,324 shares of Common Stock outstanding as of October 31, 2011 as reported on the		

2

1		No. 37244C10 EPORTING PE		13G	
-	I.R.S. IDENT	I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) David Bonderman			
2	CHECK THE (a) o (b) o	E APPROPRIA'	TE BOX IF A MEMBER OF A	GROUP*	
	. ,				
3 4		SEC USE ONLY CITIZENSHIP OR PLACE OF ORGANIZATION			
	United States				
		5	SOLE VOTING POWER		
	NUMBER OF		-0-		
	SHARES BENEFICIALLY	6	SHARED VOTING POWER		
	OWNED BY		1,410,273		
	EACH REPORTING	7	SOLE DISPOSITIVE POWE	R	
	PERSON		-0-		
	WITH:	8	SHARED DISPOSITIVE PO	WER	
			1,410,273		
9	AGGREGAT	E AMOUNT E	BENEFICIALLY OWNED BY	EACH REPORTING PERSON	
	1,410,273				
10 11		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* o PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
12	4.8% (2) TYPE OF RE	EPORTING PE	RSON*		
	IN				
		*SEE IN	ISTRUCTIONS BEFORE FILI	LING OUT	

(2) Based on a total of 29,542,324 shares of Common Stock outstanding as of October 31, 2011 as reported on the Issuer's Form 10-Q, dated November 8, 2011.

1		P No. 81943P10 REPORTING P					
	I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)						
2							
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States						
	NUMBER OF	5	SOLE VOTING POWER				
			-0-				
	SHARES BENEFICIALLY OWNED BY	6	SHARED VOTING POWER				
			1,410,273				
	EACH REPORTING	7	SOLE DISPOSITIVE POWER				
	PERSON		-0-				
	WITH:	8	SHARED DISPOSITIVE POWER				
			1,410,273				
9	AGGREGA'	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	1,410,273						
10 11		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* $\sigma$ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
12	4.8% (3) TYPE OF R	4.8% (3) TYPE OF REPORTING PERSON*					
	IN						
	*SEE INSTRUCTIONS BEFORE FILLING OUT						

(3) Based on a total of 29,542,324 shares of Common Stock outstanding as of October 31, 2011 as reported on the Issuer's Form 10-Q, dated November 8, 2011.

Item Name of Issuer:

1(a).

Genomic Health, Inc. (the "Issuer").

Item Address of Issuer's Principal Executive Offices:

1(b).

301 Penobscot Drive Redwood City, CA 94063

Item Name of Person Filing:

2(a).

This Amendment No. 1 ("Amendment 1") to Schedule 13G (as amended, the "Schedule 13G") is being filed jointly on behalf of TPG Group Holdings (SBS) Advisors, Inc., a Delaware corporation ("Group Advisors"), David Bonderman and James G. Coulter (each, a "Reporting Person" and, together, the "Reporting Persons"), pursuant to an Agreement of Joint Filing incorporated by reference herein in accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Group Advisors is the general partner of TPG Group Holdings (SBS), L.P., a Delaware limited partnership, which is the sole member of TPG Holdings I-A, LLC, a Delaware limited liability company, which is the general partner of TPG Holdings I, L.P., a Delaware limited partnership, which is the sole member of each of (i) TPG Ventures GenPar Advisors, LLC, a Delaware limited liability company ("Ventures GenPar Advisors"), and (ii) TPG Biotechnology GenPar Advisors, LLC, a Delaware limited liability company ("Biotechnology GenPar Advisors"). Ventures GenPar Advisors is the general partner of TPG Ventures GenPar, L.P., a Delaware limited partnership, which is the general partner of TPG Ventures, L.P., a Delaware limited partnership ("TPG Ventures"), which directly holds 423,081 shares of the Common Stock of the Issuer (the "Ventures Shares") reported herein. Biotechnology GenPar Advisors is the general partner of TPG Biotechnology GenPar, L.P., a Delaware limited partnership, which is the general partner of TPG Biotechnology L.P., a Delaware limited partnership, which is the general partner of TPG Biotechnology L.P., a Delaware limited partnership ("TPG Biotech" and, together with TPG Ventures, the "TPG Funds"), which directly holds 987,192 shares of the Common Stock of the Issuer (the "Biotech Shares" and, together with the Ventures Shares, the "Shares") reported herein. Because of Group Advisors' relationship to the TPG Funds, Group Advisors may be deemed to beneficially own the Shares.

David Bonderman and James G. Coulter are officers, directors and sole shareholders of Group Advisors and therefore may be deemed to beneficially own the Shares. Messrs. Bonderman and Coulter disclaim beneficial ownership of the Shares except to the extent of their pecuniary interest therein.

Item Address of Principal Business Office or, if none, Residence: 2(b).

The principal business address of each of the Reporting Persons is as follows:

c/o TPG Global, LLC 301 Commerce Street, Suite 3300 Forth Worth, Texas 76102

Item 2(c).	Citizenship:				
	See responses to Item 4 on each cover page.				
Item	Title of Class of Securities:				
2(d).	Common Stock, par value \$0.0001 per share ("Common Stock").				
Item	CUSIP Number:				
2(e).	37244C101				
Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n):					
(a)	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).				
(b)	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).				
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).				
(d)	Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).				
(e)	Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).				
(f)	Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).				
(g)	Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).				
(h)	Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (13 U.S.C. 1813).				
(i)	Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).				
(j)	Non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).				
(k)	Group in accordance with §240.13d-1(b)(1)(ii)(K).				
If filin	26.2				

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

6

#### Item 4.Ownership.

(a) Amount Beneficially Owned:

See responses to Item 9 on each cover page.

(b) Percent of Class:

See responses to Item 11 on each cover page.

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote:

See responses to Item 5 on each cover page.

(ii) Shared power to vote or to direct the vote:

See responses to Item 6 on each cover page.

(iii) Sole power to dispose or to direct the disposition of:

See responses to Item 7 on each cover page.

(iv) Shared power to dispose or direct the disposition of:

See responses to Item 8 on each cover page.

Item 5.Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	Not Applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
	See response to Item 2(a) above.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable.
Item 9.	Notice of Dissolution of Group.
	Not Applicable.
Item 10.	Certification.
	Not Applicable .

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2012

TPG Group Holdings (SBS) Advisors, Inc.

By: /s/ Ronald Cami Name: Ronald Cami Title: Vice President

David Bonderman

By: /s/ Ronald Cami

Name: Ronald Cami, on behalf of David Bonderman (4)

James G. Coulter

By: /s/ Ronald Cami

Name: Ronald Cami, on behalf of James G. Coulter (5)

<sup>(4)</sup> Ronald Cami is signing on behalf of Mr. Bonderman pursuant to an authorization and designation letter dated July 1, 2010, which was previously filed with the Securities and Exchange Commission ("Commission") as an exhibit to a Form 13D filed by Mr. Bonderman on July 26, 2010.

<sup>(5)</sup> Ronald Cami is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated July 1, 2010, which was previously filed with the Commission as an exhibit to a Form 13D filed by Mr. Coulter on July 26, 2010.

#### Exhibit Index

Exhibit 1 Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934.\*

<sup>\*</sup> Incorporated herein by reference to the Agreement of Joint Filing by TPG Advisors II, Inc., TPG Advisors III, Inc., TPG Advisors V, Inc., TPG Advisors VI, Inc., T3 Advisors, Inc., T3 Advisors II, Inc., TPG Group Holdings (SBS) Advisors, Inc., David Bonderman and James G. Coulter, dated as of February 14, 2011, which was previously filed with the Commission as Exhibit 1 to Schedule 13G filed by TPG Group Holdings (SBS) Advisors, Inc., David Bonderman and James G. Coulter on February 14, 2011.